pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2011
- Employees
- 741
- Programs
- 8
- Drugs
- 9
- Patents
- 0
Blueprint Medicines projects
8 ClinicalTrials.gov programs sponsored by Blueprint Medicines.
Blueprint Medicines has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BLU-263-1201
Blueprint Medicines (Netherlands) B.V.
Indolent Systemic Mastocytosis and SSM
1 trial -
Elenestinib
Blueprint Medicines (Netherlands) B.V.
Indolent Systemic Mastocytosis
1 trial -
avapritinib
Blueprint Medicines (Netherlands) B.V.
GIST
1 trial -
AZACITIDINE
Blueprint Medicines (Netherlands) B.V.
Advanced Systemic Mastocytosis
1 trial -
BLU-285-2203
Blueprint Medicines (Netherlands) B.V.
Indolent Systemic Mastocytosis (ISM)
1 trial -
BLU-285-3101
Blueprint Medicines (Netherlands) B.V.
Solid Tumors Dependent on KIT or PDGFRA Signaling
1 trial -
BLU-808-1201
Blueprint Medicines (Netherlands) B.V.
Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
1 trial -
Avapritinib, Avapritinib
Blueprint Medicines (Netherlands) B.V.
Systemic Mastocytosis
1 trial
Frequently asked questions
How many clinical projects does Blueprint Medicines have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.